Recent 8-K filings for VYNE

• March 11, 2026, 7:59 PM ET regulatory materiality 0.60 negative item 3.01 ◈ Listing & Compliance Notices

  VYNE receives Nasdaq extension to Sept 7, 2026 to regain $1 bid price compliance

  Company failed to regain minimum $1.00 bid price by original March 10, 2026 deadline.

• December 17, 2025, 6:59 PM ET M&A materiality 0.95 negative item 1.01item 3.02item 5.01item 5.02item 7.01item 9.01

  VYNE Therapeutics to merge with Yarrow Bioscience; Yarrow stockholders to own ~97% of combined company

  Pro forma ownership: pre-Merger Yarrow stockholders ~97%, VYNE stockholders ~3%.

• November 6, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  VYNE reports Q3 net loss $7.3M; cash $32.7M; strategic review ongoing

  Net loss $7.3M ($0.17 per share) vs $12.2M ($0.29) in Q3 2024; revenue $0.2M from Finacea royalty.

• September 12, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices

  VYNE receives Nasdaq bid price deficiency notice; 180-day cure period to March 2026

  Closing bid price of VYNE common stock below $1.00 for 30 consecutive business days.

• August 14, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 5.02item 9.01

  VYNE Q2 net loss $5.8M; cash runway extended to H1 2027; two directors resign

  Cash, equivalents and marketable securities $39.6M as of Jun 30, expected to fund ops into first half of 2027.

• July 30, 2025, 7:59 PM ET other material materiality 0.90 negative item 2.02item 8.01item 9.01

  VYNE Phase 2b Repibresib vitiligo trial misses F-VASI50, terminates extension, seeks partner

  Primary endpoint F-VASI50 at Week 24 not met: 19.5% for 3% vs 23.4% vehicle (p=0.1245).

• May 8, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  VYNE Q1 net loss $8.6M; VYN202 psoriasis trial on clinical hold; repibresib vitiligo data due mid-2025

  Cash $50.3M; net loss $8.6M ($0.20/sh) vs $6.2M in Q1 2024.

• March 6, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  VYNE reports FY2024 net loss $39.8M; cash $61.5M; repibresib Phase 2b data due mid-2025

  Cash & equivalents total $61.5M as of Dec 31, 2024; expected runway into 2H 2026.

• December 23, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  VYNE reports positive Phase 1a MAD data for VYN202; no AE, robust biomarker activity

  VYN202 showed favorable safety with no drug-related AEs, including no thrombocytopenia or neutropenia.

• November 7, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  VYNE reports Q3 net loss $12.2M; VYN201 Phase 2b enrollment exceeds target, top-line mid-2025

  Net loss of $12.2M ($0.29/sh) in Q3 2024 vs $6.6M ($2.01/sh) in Q3 2023, driven by higher R&D spend.

• September 12, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  VYNE Therapeutics reports positive Phase 1a SAD data for VYN202; no drug-related adverse events

  VYN202 well tolerated across all dose groups; no serious or drug-related AEs, no clinically significant lab/ECG abnormalities.

• August 14, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  VYNE Therapeutics Q2 2024 net loss $9.4M; cash $78.1M funds milestones into 2025

  Net loss of $9.4M ($0.22 EPS) vs $10.1M ($3.09 EPS) in Q2 2023.

• May 9, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  VYNE reports Q1 2024 net loss of $6.2M, cash $86M; vitiligo Phase 2b trial on track

  Cash, equivalents, restricted cash and marketable securities of $86.0M as of March 31; runway through end of 2025.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.65 · Most common event earnings

2 positive 7 negative 9 neutral

source · VYNE on sec.gov